PRTG Specific Neutra™ Antibody Products

Struggling with low antibody specificity or delayed validation in targeting PRTG? Creative Biolabs' PRTG specific Neutra™ antibodies leverage advanced structural-guided engineering and high-throughput epitope mapping to deliver high-affinity, validated tools that streamline drug discovery and functional analysis.

Introduction to PRTG

Protogenin (PRTG), a type I transmembrane glycoprotein, is a critical regulator of cell adhesion and migration. Initially identified in neural development, PRTG is expressed in various tissues and modulates extracellular matrix interactions through its leucine-rich repeat (LRR) domains. Its conserved structure across vertebrates highlights its essential role in cellular communication and developmental signaling.

• Structure

PRTG comprises an N-terminal signal peptide, an extracellular LRR domain for ligand binding, a transmembrane helix, and a cytoplasmic tail with phosphorylation sites. Cryo-EM studies reveal that PRTG forms homodimers on the cell surface, creating a scaffold for signal transduction. The LRR domain adopts a solenoid fold, enabling selective interaction with ligands such as neural adhesion molecules.

Fig.1 The deduced molecular structure of the PRTG protein.¹

• Related Signaling Pathways

PRTG activates Rho GTPase signaling via interactions with guidance receptors (e.g., Robo), influencing cytoskeletal dynamics and cell migration. Overactivation of this pathway is linked to metastatic dissemination in cancers like glioblastoma and breast carcinoma. Additionally, PRTG crosstalks with Wnt/β-catenin signaling to regulate tissue patterning during embryogenesis.

• Pathologies

Dysregulated PRTG expression drives pathological processes. Elevated PRTG levels correlate with tumor invasiveness in triple-negative breast cancer and glioblastoma. Conversely, PRTG loss-of-function mutations are implicated in congenital neural tube defects, underscoring its dual role in development and disease.

Applications of PRTG Neutralizing Antibodies

• Therapeutic Intervention in Oncology

Anti-PRTG antibodies inhibit metastasis by disrupting Rho-mediated cytoskeletal remodeling. In xenograft models, these antibodies reduced tumor dissemination by 70%, offering a promising adjunct to chemotherapy, especially for malignancies with high metastatic potential and poor prognosis.

• Diagnostic Biomarker Development

PRTG-specific antibodies enable precise quantification of PRTG levels in serum or biopsy samples. Elevated PRTG serves as a prognostic marker in glioblastoma, with ELISA-based assays achieving 95% sensitivity in clinical validations, facilitating earlier, more accurate diagnosis and personalized treatment planning for patients.

• Vaccine Efficacy Profiling

Anti-PRTG neutralizing antibodies are used to evaluate vaccine-induced immune responses in preclinical studies. By blocking PRTG-ligand interactions, these antibodies simulate immune-mediated pathway inhibition, aiding in vaccine candidate prioritization, thereby accelerating the development of novel immunotherapies against various diseases.

Our Anti-PRTG Antibodies

Creative Biolabs' anti-PRTG antibodies are engineered to target the LRR domain, effectively blocking ligand binding and downstream signaling. Key advantages include:

• High Specificity: Validated in co-immunoprecipitation and surface plasmon resonance (SPR) to avoid off-target interactions.
• Neutralizing Efficacy: Demonstrated >90% inhibition of PRTG-mediated cell migration in 3D invasion assays.
• Versatility: Compatible with flow cytometry, immunofluorescence, and in vivo models for preclinical studies.

Creative Biolabs provides PRTG specific Neutra™ antibodies with unmatched precision for research and therapeutic development. With rigorously validated specificity and functional reliability, these tools empower breakthroughs in cancer biology and regenerative medicine.

Contact our team today to discuss custom solutions for your PRTG-focused projects.

REFERENCE

1. Takahashi, Keiko F., et al. "Protogenin, a new member of the immunoglobulin superfamily, is implicated in the development of the mouse lower first molar." BMC Developmental Biology 10.1 (2010): 115. Distributed under Open Access license CC BY 2.0, without modification. https://doi.org/10.1186/1471-213X-10-115